3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Lymphoma, Mantle-Cell
5
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Recurrence
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, B-Cell
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
Peripheral Blood Stem Cell Transplantation
19
fludarabine phosphate
13
Mycophenolic Acid
12
Whole-Body Irradiation
11
Tacrolimus
11
Cyclosporine
9
Psychiatric Rehabilitation
8
Cyclophosphamide
8
Therapeutics
7
Rituximab
6
Methotrexate
6
Flow Cytometry
5
Busulfan
5
Vorinostat
4
Polymerase Chain Reaction
4
Methylprednisolone
4
Filgrastim
4
merphos
3
Radiotherapy
3
Ondansetron
3
Interferon-alpha
3
Etoposide
3
Early Intervention, Educational
3
Dexamethasone
3
Calcium Dobesilate
3
Bortezomib
3
Alemtuzumab
3
obinutuzumab
2
liposomal amphotericin B
2
immunotoxin HA22
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Hairy Cell
×
acalabrutinib
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts